Pd 1 mab

Manufactured by BioXCell

Sourced in United States

PD-1 mAb is a monoclonal antibody that specifically binds to the Programmed Cell Death 1 (PD-1) receptor. PD-1 is an immune checkpoint protein expressed on the surface of T cells, B cells, and other immune cells. The core function of PD-1 mAb is to block the interaction between PD-1 and its ligands, PD-L1 and PD-L2, thereby modulating immune responses.

Automatically generated - may contain errors

Lab products found in correlation

Oncoad, by BioXCell (1 mentions) Zombie nir dye, by BioLegend (1 mentions) Hamster igg, by BioXCell (1 mentions) Cd11b, by BioLegend (1 mentions) F4 80, by BioLegend (1 mentions) Tim 3, by BioLegend (1 mentions) Ifn γ, by BioLegend (1 mentions) Cd206, by BioLegend (1 mentions) Cd62l, by BioLegend (1 mentions) Cd103, by BioLegend (1 mentions) Arginase 1, by BioLegend (1 mentions)

Spelling variants of this product

Anti-PD-1 mAb (11 citations) Anti-PD-1 mAb (clone RMP1-14; (8 citations) Anti-mouse PD-1 MAb (4 citations) Anti—PD-1 mAb (clone J43) (2 citations)

3 protocols using pd 1 mab

Combination Therapy Inhibits Tumor Growth

Check if the same lab product or an alternative is used in the 5 most similar protocols

Six-week-old BALB/c mice were purchased from Shanghai SLAC Animal Laboratory Co. Ltd. (Shanghai, China) and fed at the Animal Center of Tongji University. CT26 cells (1 × 10⁶ cells) were administered into the right limbs of BALB/c mice. Tumor size was determined on the indicated days using the formula (width)² × length/2. After the tumor grew into 100 mm³, mice were treated with different strategies and segregated into four groups according to the tumor therapy received: phosphate-buffer saline (PBS), STAT3 inhibitor (5 µM, MedChemExpress, New Jersey, USA), PD-1 mAb (10 µg/mL, Bioxcell, Lebanon, NH, USA) or combinatorial treatment with STAT3 inhibitor (5 µM) and PD-1 mAb (10 µg/mL), a replicate for each treatment group for each day for intraperitoneal injection. At the endpoint of experiments, all mice were euthanized, and organs were harvested for flow cytometry and histopathological analysis.

Huang L., Zhao Y., Shan M., Wang S., Chen J., Liu Z, & Xu Q. (2023). Targeting crosstalk of STAT3 between tumor-associated M2 macrophages and Tregs in colorectal cancer. Cancer Biology & Therapy, 24(1), 2226418.

+ Open protocol

+ Expand

Combinatorial Cancer Immunotherapy in Mice

Check if the same lab product or an alternative is used in the 5 most similar protocols

Six‐week‐old BALB/c mice were included in the study. CT26 cells (5 × 10⁵ cells) were administered into the right limbs of immunocompetent BALB/c mice. Seven days after tumor cell injection (day 0), tumors were measured using the formula (width)² × length/2. Mice were segregated into four groups according to the tumor therapy received: PBS, Onco^Ad (5 × 10⁸ VPs of each virus in 100 μl), PD‐1 mAb (10 μg ml⁻¹; Bioxcell) or combinatorial treatment with Onco^Ad (5 × 10⁸ VPs of each virus in 100 μl) and PD‐1 mAb (10 μg ml⁻¹; Bioxcell). On day 0, Onco^Ad or PBS were directly injected into the tumor. A second dose (PBS, Onco^Ad [5 × 10⁸ VPs of each virus in 100 μl]) was administered on day 4. Anti‐PD‐1 therapy developed herein was administered on days 8, 10, and 12 intraperitoneally, and a replicate for each treatment group for each day. On day 14, all mice were euthanized and organs were harvested for flow cytometry and histopathological analysis.

Huang L., Zhao H., Shan M., Chen H., Xu B., He Y., Zhao Y., Liu Z., Chen J, & Xu Q. (2022). Oncolytic adenovirus H101 ameliorate the efficacy of anti‐PD‐1 monotherapy in colorectal cancer. Cancer Medicine, 11(23), 4575-4587.

+ Open protocol

+ Expand

Tumor Immunotherapy Protocol with PD-1 mAb and HSA-IL21

Check if the same lab product or an alternative is used in the 5 most similar protocols

HSA-IL21 (the half-life extended IL21 was kindly provided by Anwita Biosciences, CA, USA), PD-1mAb (clone:J43), hamster IgG were purchased from Bioxcell company (catalog no. BE0091) for tumor therapy. For Flow cytometry, CD45 (clone: 30-F11), CD4 (clone: GK1.5), CD8 (clone: 53–6.7), NK1.1 (clone: PK136), B220 (clone: RA3-6B2), Foxp3 (MF-14), PD-1(29F.1A12), Tim-3 (clone: RMT3-23), Lag-3 (clone: C9B7W), CD39 (clone: 24DMS1), CD62L (clone: MEL-14), CD44 (clone: IM7), CD103 (clone: M290), CD69 (clone: H1.2F3), IFN-γ (clone: XMG1.2), GzmB (clone: QA16A02), CD11b (clone: M1/70), Ly6C (clone: HK1.4), Ly6G (clone: 1A8), Gr-1 (clone: RB6-8C5), CD24 (clone: M1/69), F4/80 (clone: BM8), CD11C (clone: N418), CD206 (clone: MR6F3), Arginase 1 (clone: A1exF5) were purchased from Biolegend ebioscience or BD Bioscience. Zombie NIR dye was purchased from Biolegend.

Wu S., Sun R., Tan B., Chen B., Zhou W., Gao D.S., Zhong J., Huang H., Jiang J, & Lu B. (2021). The Half-Life-Extended IL21 can Be Combined With Multiple Checkpoint Inhibitors for Tumor Immunotherapy. Frontiers in Cell and Developmental Biology, 9, 779865.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!